| INTRODUCTION
Differentiation of "localized" cancer (stages I and II) from "metastatic" cancer (stages III and IV) is widely used to decide whether or not systemic chemotherapy is required after surgery for many cancer subtypes. Specifically, patients with metastatic cancers (cancers that spread from the primary tumor site) are generally treated with adjuvant chemotherapy; however, such therapies will be avoided owing to their adverse side effects in patients with localized cancer that can be removed through surgery. First introduced in the 1970s, 1 surgical biopsy and histology of the so-called sentinel lymph node(s)-the lymph node(s) draining a primary tumor site-have become the gold standard in differentiating localized from metastatic solid cancers. 2 It has become a standard of care in breast cancer, cutaneous melanoma management (at least for patients without obvious metastases: large secondary cancers or palpable lymph nodes), 3 and is being increasingly used in the management in a number of other solid tumor cancer types, including colon, head and neck, penile, gastric, lung, and gynecologic. 4 Lymph node biopsy typically involves 3 steps: 1) in vivo mapping/ localization of the lymphatics draining a primary tumor, 2) surgical removal of the sentinel lymph node(s), and 3) histological assessment of the resected nodes to identify the presence or absence of metastatic cancer. Considerable variability exists in the protocols used within each step. For example, lymph node mapping has been carried out with lymphoscintigraphy, x-ray computed tomography, near-infrared fluorescence, etc, 5 all using various imaging agents to add contrast to the lymphatics. Surgical approaches vary from institute-to-institute and surgeon-to-surgeon, and can include microsurgical methods to minimize risks of lymphedema. 6 Finally, methods of lymph node histology can involve standard hematoxylin and eosin (H&E) staining, touchpreparation cytology, 7 rapid cytokeratin immunohistochemistry, 8 onestep nucleic acid amplification, 9 flow cytometry, 10 and immunomagnetic separation. 11 A full examination of the various protocols used or proposed in the literature at each step of lymph node biopsy is out the scope of this article; however, the reader is directed to a number of excellent reviews and seminal articles for further details. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Even with sentinel lymph node biopsies, which are associated with far lower rates of morbidity than more complete lymph node dissections (eg, complete axillary lymph node dissection in breast cancer management 30 ), there remain risks of postsurgical patient pain/discomfort, nerve damage, and lymphedema. 31, 32 Moreover, conventional histological analyses are laborious and can delay subsequent procedures. In response to these limitations in standard lymph node biopsy protocols, considerable efforts from a number of clinical and research groups have been focused on developing and testing methods capable of "staging" lymph nodes noninvasively, ie, detecting the presence or absence of cancer in tumor-draining lymph nodes through imaging, rather than surgery and pathology. Potential noninvasive imaging solutions now span nearly every common (and experimental) imaging modality, with most applications requiring the administration of some type of imaging agent to improve lymphatic or cancer cell contrast. In this review article, the methods that have been developed for noninvasive lymph node staging are categorized into 4 areas that are as follows:
1. Imaging agent-free methods-those that capitalize on intrinsic signals specific to cancer-bearing nodes compared to cancer-free nodes.
2.
Nontargeted imaging agent methods-those that use administration of a lymphatic contrast agent in an attempt to improve identification of abnormal lymph node based on either structure/morphology or function.
3. Metabolic imaging agent methods-those that use imaging agents that exhibit uptake and retention in tissue based on metabolic processes that may be upregulated in cancers (eg, glucose, thymidine, and choline analogs). 
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MRI has the potential to directly image lymph node morphology as well; however, the morphology-dependent analyses have had limited success in detecting lymph node metastases, with sensitivity range from 24% to 85%. [34] [35] [36] Several groups of investigators have reported more promising results by using diffusion-weighted MRI, and it is now being used to evaluate nodal status in a number of applications. [37] [38] [39] [40] Magnetic resonance spectroscopy has also been used to look at the nodal status. 41 Photoacoustics has also emerged as a for many decades in many applications (eg, cancer, neurodegenerative disorders, and cardiac disease). 58, 59 Yet widespread adoption for any application in the clinic has remained elusive to date.
In 2008, Sampath et al 60 provided a thorough summary and history of molecular targeted imaging agent methods for lymph node staging.
To provide a framework for a discussion of the advances made since that work, a brief summary of Sampath et al is warranted. The field was founded on nuclear medicine studies dating back to the 1970s, where 131 I-labeled antiferrin immunoglobulin retention in lymph nodes was observed to correlate with breast carcinoma and lymphoma positive nodes. 61 Subsequently, a number of clinical trials were carried out using "immunolymphoscintigraphy" (gamma camera imaging of lymphatics after intradermal injection of radioactive, cancer-targeted antibodies) to noninvasively assess nodal tumor burden in various applications (cancer types, molecular targets). [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] The majority of these studies reported sensitivity rates of greater than 80%; however, specificity was often a problem. Significant levels of false positives occurred as a result of nonspecific retention of imaging agents in tumor-free nodes that was caused by slow clearance rates (~48 h). 
| Pharmacokinetic considerations
The pharmacokinetics of imaging agents are influenced by many factors including imaging agent properties (eg, size, charge, and lipophilicity), route of imaging agent administration (eg, intravenous vs intradermal), and physiology (eg, blood/lymph flow, vascular permeability, and rates of excretion). The ideal imaging agent would likely rapidly perfuse throughout every tissue of the body, quickly bind (with high affinity) to the targeted biomolecule, and the imaging agent that was not specifically bound would then rapidly washout from the system. Yet there are a number of hurdles in achieving these ideal properties. The chemistry of imaging agents is a mature field that is continually advancing. For a more complete discussion, the reader is referred to a number of recent review articles on the subject. [108] [109] [110] [111] [112] There are a few principles worth expanding on here in the context of molecular targeted nodal staging. One is centered on the route of administration.
To generalize, imaging agents can either be injected systemically (typically intravenously) or locally (typically interstitially, proximal to the primary tumor). Conventional molecular imaging usually uses systemic injection, and this method has also been used for a number of molecular targeted nodal staging applications (see Table 1 ). In these applications, the imaging agent is delivered to tissues through the blood, so for it to gain access to a specific lymph node, it must first extravasate out of the blood and into the interstitial space of the tissues that are drained by the specific lymph node. Then, it has to be transported through the lymphatics to the node, where it has a chance to bind specifically to whatever cancer-specific biomolecule it is targeted to (then unbound agent needs time to wash out). In some respects, this may seem highly inefficient because the vast majority of the imaging agent will be delivered to tissues drained by nodes that may be of no interest at all to the imaging application. However, there are a couple of key advantages to this approach. First, individual lymph nodes have multiple input (afferent) vessels, 113 and it is known that metastases can block one or more afferent vessels 114 ; therefore, systemic injection ensures that the imaging agent will have the greatest chance of accessing the lymph node because it will arrive at all afferent vessels. Moreover, highly diffusible imaging agents may be able to gain access to the lymph node directly through the nodeʼs own blood supply, circumventing the need to enter the node through the lymphatics (which may be blocked). Another advantage of systemic administration is that it enables the use of smaller imaging agents that have shorter biological half-lives 110, 115 (Note: as detailed in the following paragraph, local administration requires large imaging agents). This, in turn, allows for imaging of molecular targeted contrast at earlier time points after injection, which can be particularly beneficial in nuclear medicine studies, where radioactive decay rates must be taken into account.
Lymph node mapping methods 15, 116, 117 used clinically in all lymph node biopsy applications use a local injection of contrast agents
Tc-colloid, methylene blue). For these approaches to work, a significant fraction of the injected agent must be taken up preferentially by lymphatic vessels rather than blood vessels (to achieve contrast in lymph nodes compared with surrounding tissue). In general, at least with hydrophilic imaging agents, the larger the imaging agent, more likely it is to be taken up by the lymphatics, 118, 119 and it has been demonstrated that agents with molecular weights greater than 16 kDa will have more than 50% absorption into the lymphatics after subcutaneous injection. 120 A number of molecular targeted nodal staging methods that use sufficiently large imaging agents have also used this local administration (see Table 1 ), and they have a unique set of benefits compared with systemic injection methods. First, because the majority of the injected dose will pass through the lymph nodes of interest, local injection makes it possible to use far lower doses of imaging agent compared with systemic injection. This may be helpful for patient safety and clearing regulatory hurdles. Second, at least at early time points after injection, the majority of the imaging agent will be confined to the lymphatics, such that background signals may be very low or negligible depending on the imaging modality being used. In addition to the obvious benefits of minimizing background signal, this may be particularly helpful for fluorescence imaging applications, which are highly "surface-weighted" in terms of their sensitivity. That is, fluorescence created at the surface will be detected as much brighter than a similar level of fluorescence created at depth. 17, 121, 122 Ultimate depths sensitivities are limited to a few centimeters depending on the wavelength of the fluorescence, the system geometry and sensitivity, and method of data collection (for more details, see the section on depth sensitivity).
There are also some significant drawbacks to local injection methods that are likely the reason why they have not been widely adopted in the clinic despite first being proposed in the 1970s. 1 First, larger imaging agents, like the ones required for local administration, also have longer residual times at the site of injection. 118 This, coupled with the fact that they tend to have longer biological halflives, 110 means by the time the unbound imaging agent washes away, molecular contrast can be confounded by background signal. Second, there is substantial variability in lymph flow rates among nodes and for different sites of injection. 47, 48 This can be problematic for setting a threshold on what level of imaging agent concentration would be indicative of cancer burden. Finally as mentioned, delivery of imaging agents to lymph nodes may be significantly mitigated by the presence of cancer in a lymph node blocking one or more afferent vessels.
With a local injection, the site of injection may only have access to a node through a single afferent vessel. All of these complications can increase the risk of both false positives (cancer-free nodes being identified as cancer bearing) and false negatives (cancer-bearing nodes being identified as cancer free).
In fact, lymph node and cancer physiology, rather than cancerspecific binding, can dominate the pharmacokinetics of imaging agents in terms of their accumulation and retention in lymph nodes for both systemically 123 and locally 60 delivered methods. To account for this, a growing number of groups have been using so-called paired-agent or ratiometric imaging methods. Another complication with paired-agent imaging, in general, is that even when equal concentrations of both the targeted and control imaging agents are injected, signals may not be on the same scale owing to differences in: 1) quantum efficiency between the agents, 2) detection sensitivity of the imaging system in the "channels" used to image each imaging agent (including light source and detector differences), and 3) tissue properties at the respective wavelengths. Quantum efficiency and system sensitivity differences can be corrected for using a calibration standard or imaging of a diluted stock solution of the injected cocktail of imaging agents. Correction for tissue optical property effects is more complicated. One method to correct for these effects is to normalize signals from targeted and control imaging agents in lymph nodes at early time points after paired-agent injection when delivery of both agents is expected to be equivalent. 134, 138 However, it may not be feasible/preferable to collect fluorescence uptake and retention in the lymph nodes for long periods of time.
| PAIRED-AGENT AND RATIOMETRIC METHODS
Instead, it will likely be preferable to use only paired-agent lymph LI ET AL.
| 309
node imaging at a single optimal time after injection when the estimation of cancer burden is optimal. In this case, another method of imaging agent detection normalization is preferred. One method to correct for optical property effects in fluorescence imaging is Born normalization, 139 wherein the measured fluorescence is divided by the measured light used to excite each fluorophore that is remitted from the tissue. This optical property normalization can be carried out in an even more sophisticated manner by a full spectral analysis of the tissue, 140 or by faster methods that map optical properties on a wider field of view. 141 Alternatively, it is possible to avoid the need for optical property correction by using targeted and control agents that have emission profiles in the same wavelength range but with different fluorescence lifetimes. 142 Similarly, the usage of surface-enhanced
Raman scattering particles instead of fluorophores can enable high levels of multiplexing with narrow wavelength ranges.
143,144
| Depth sensitivity considerations
To date, all of the paired-agent and ratiometric methods have required optical imaging strategies for signal detection. As mentioned previously, depth sensitivity is limited for optical imaging of biological tissue, and most human applications are confined to imaging of the skin, surgical margins, or using endoscopic procedures. Lymph nodes can be found at any depth in the human; however, nodes that are involved in breast cancer, head and neck cancer, and skin cancers are on an average within 1 cm of the skin surface, 145 making them accessible to optical imaging strategies. In the absence of background signal (ie, if the majority of the imaging agent is confined to the lymphatics), as would be expected in locally administered imaging agent applications, it is possible to observe fluorescence signal from most nodes in patients with breast cancer. 146 This was observed after local injection of ICG, which fluoresces in the near infrared (~800 nm) where tissue absorption is low, without using any specialized equipment. Depth sensitivity and discrimination can be improved through a number of approaches, including time-domain fluorescence detection with isolation of late-arriving photons, 147, 148 masked detection of structured light illumination, 149 spectral analysis, 150 multiple source-detector distances, 151 and US-guided tomography 152 ; however, an ultimate depth sensitivity of anything more than a few centimeters is inconceivable at this point. For further increases in depth sensitivity, marginal gains can be achieved by adapting pairedagent imaging to multispectral photoacoustic imaging methods. 42, 133, [153] [154] [155] For deeper applications (eg, prostate, lung, and gastric), paired-agent imaging could be adapted to dual-isotope single-photon emission computed tomography or lymphoscintigraphy. 156 
| CONCLUSIONS AND PERSPECTIVES ON MOLECULAR TARGETED LYMPH NODE STAGING
Molecular targeting ultimately has the potential to be more sensitive than all other noninvasive imaging methods for lymph node staging because tumor burden must be significant before it produces changes in lymph node morphology, function, or metabolism that is observable by the agent-free, nontargeted agent, and metabolic agent methods summarized. However, despite clinical applications of molecular lymph node staging dating back to the 1970s, nonspecific imaging agent accumulation and imaging agent delivery variability have diminished sensitivity and specificity of the methods, such that widespread adoption has not been realized. Recent approaches using paired-agent and ratiometric molecular imaging methods have shown extraordinary promise in animal models to overcome the effects of lymph node physiology on molecular targeted imaging agent contrast, allowing microscopic levels of cancer burden to be detectable on wide-field-of-view imaging. Clinical translation of these methods will require intelligent selection of a suitable molecular target or targets, which will likely depend on the cancer type, and perhaps the individual patient. Furthermore, the location of the lymph nodes of interest will likely define the optimal imaging system with optical imaging providing promise for superficial nodes, photoacoustic imaging for slightly deeper nodes, and single-photon emission computed tomography of lymphoscintigraphy for deeper nodes.
